Volition is a multi-national company developing simple, easy to use blood-based tests to accurately diagnose a range of cancers. Volition's proprietary Nu.Q™ immunoassay technology uses an array of simple, cost-effective blood based tests to identify very early ‘nucleosomic’ markers of cancer. Our Nu.Q™ technology represents a powerful step-change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis. Our first test, the Nu.Q™ colorectal cancer screening triage test, identifies patients who have received a false positive result on their FIT test and ensures that fewer patients are referred for unnecessary colonoscopies. Diagnostic Nu.Q™ tests for people with symptoms indicating colorectal cancer as well as a screening test for average risk populations are in development.
Brands: The Nu.Q™ colorectal cancer screening triage test identifies patients with a false positive result on their FIT test and ensure that fewer patients are referred for unnecessary colonoscopies.
DDW Tracks Technologies and Procedural Innovations
Does your company only service US attendees? No
Is your company a new exhibiting company? Yes